An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum

Part of paid clinical trials in Gahanna, Ohio.

Sponsor
Ohio State University
Study ID
NCT03137160
Phase
PHASE2
Status
Completed

Conditions

  • Pyoderma Gangrenosum

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

Study Details

An Open-Label, Proof-Of-Concept, Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum

Key Dates

Start date
May 4, 2017
Status verified
Feb 2024
Primary completion
Aug 16, 2018
Completion
Aug 16, 2018

Study Design

Enrollment
4 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ixekizumab (Taltz)
    We have received funding for only a small pilot study to prove a benefit from Interleukin-17 inhibition in Pyoderma Gangrenosum . Therefore, there is only one treatment arm. The primary outcome will be a comparison of week 12 to baseline regarding a two-point improvement in the Investigator Global Assessment.

Primary Outcome Measure

The Proportion of Subjects Achieving 2-point Reduction in the 5-point Investigator Global Assessment (IGA) for the Target Ulcer at Week 12 [ Time Frame: 12 Weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
The Ohio State University DermatologyGahannaOhio43230-

Find similar trials in Gahanna, OH

By research site
The Ohio State University Dermatology· Gahanna, OH

Related Studies